Scholarlink

Background/aims <p>This study aimed to investigate the effects of Elabela peptide (ELA) levels in non-ST-segment elevation myocardial infarction (NSTEMI) patients presenting to the emergency department (ED) with cardiac chest pain to investigate the efficacy of ELA in predicting major adverse cardiac events (MACE).</p> Methods <p>Our single-center, prospective study involved NSTEMI patients admitted to ED between June 2023 and June 2024. Serum ELA levels were determined by enzyme-linked immunosorbent assay using commercial kits. The performance of the ELA in predicting MACE and discriminating the NSTEMI group was evaluated by the receiver operating characteristic (ROC) analysis and the area under the curve (AUC).</p> Results <p>A total of 119 patients participated in this study: 64 NSTEMI patients and 55 controls. There was a weak and statistically significant correlation between the high-sensitive cardiac troponin T value at admission and the ELA levels. The median ELA value of the group with and without MACE was 954 and 811&#xa0;pg/ml, respectively. There was a statistically significant difference between these groups (p = 0.049). The ability of the ELA value to predict 30-day MACE was assessed using ROC analysis, yielding an AUC of 0.652 (95% CI 0.523–0.767). The optimal cut-off point for ELA based on the Youden Index was &gt; 962&#xa0;pg/ml (sensitivity: 48.84%; specificity: 90.48%; positive likelihood ratio 5.13; negative likelihood ratio 0.57).</p> Conclusions <p>In conclusion, we propose that ELA can assist in the early diagnosis of NSTEMI patients presenting to ED with chest pain and may be an effective and supportive biomarker for predicting MACE.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic value of elabela peptide on predicting major adverse cardiac events of NSTEMI patients in emergency department

  • 期刊论文

  • 发表日期：

    2025年8月14日

查看全文
  • Fulya Erdogan,
  • Dilay Satilmis,
  • Egemen Yildiz,
  • Erdem Cevik

摘要

Background/aims

This study aimed to investigate the effects of Elabela peptide (ELA) levels in non-ST-segment elevation myocardial infarction (NSTEMI) patients presenting to the emergency department (ED) with cardiac chest pain to investigate the efficacy of ELA in predicting major adverse cardiac events (MACE).

Methods

Our single-center, prospective study involved NSTEMI patients admitted to ED between June 2023 and June 2024. Serum ELA levels were determined by enzyme-linked immunosorbent assay using commercial kits. The performance of the ELA in predicting MACE and discriminating the NSTEMI group was evaluated by the receiver operating characteristic (ROC) analysis and the area under the curve (AUC).

Results

A total of 119 patients participated in this study: 64 NSTEMI patients and 55 controls. There was a weak and statistically significant correlation between the high-sensitive cardiac troponin T value at admission and the ELA levels. The median ELA value of the group with and without MACE was 954 and 811 pg/ml, respectively. There was a statistically significant difference between these groups (p = 0.049). The ability of the ELA value to predict 30-day MACE was assessed using ROC analysis, yielding an AUC of 0.652 (95% CI 0.523–0.767). The optimal cut-off point for ELA based on the Youden Index was > 962 pg/ml (sensitivity: 48.84%; specificity: 90.48%; positive likelihood ratio 5.13; negative likelihood ratio 0.57).

Conclusions

In conclusion, we propose that ELA can assist in the early diagnosis of NSTEMI patients presenting to ED with chest pain and may be an effective and supportive biomarker for predicting MACE.